GlassScriptPhysician profile
Marvin J Slepian
NPI 1518039908
$105,575.99
in general payments reported to CMS, 2019-2025
8 companies · $289 in 2025
The $289 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $9,911 · 2021: $10K · 2022: $19K · 2023: $21K · 2024: $20K · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Honoraria: $9,000 · Travel and Lodging: $4,277 · Food and Beverage: $1,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,570.00 |
| Honoraria | $9,000.00 |
| Travel and Lodging | $4,277.11 |
| Food and Beverage | $1,107.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $87,190.02 | 2019-2024 | Xarelto |
| Abiomed | $17,686.55 | 2022-2024 | Impella |
| Impulse Dynamics (USA) INC. | $168.55 | 2025 | Optimizer |
| Arrow International, INC. | $152.86 | 2019 | |
| Paragonix Technologies, INC. | $120.88 | 2025 | Sherpapak |
| Boston Scientific Corporation | $108.44 | 2019 | |
| Acist Medical Systems, INC. | $95.75 | 2019 | |
| Medtronic, INC. | $52.94 | 2023 | Mosaic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Slepian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.